Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
27th Jan 20117:00 amBUSTransaction in Own Shares
20th Jan 20119:51 amBUSHolding(s) in Company
11th Oct 20107:00 amBUSKiotech International plc ("Kiotech") Acquisition of long leasehold interest
1st Oct 20102:29 pmRNSResult of EGM
20th Sep 20107:00 amBUSDirector/PDMR Shareholding
15th Sep 20107:00 amBUSHalf-yearly Report
7th Sep 20107:00 amBUSPosting of notice of General Meeting
6th Sep 20107:00 amBUSAcquisition of long leasehold interest
11th Aug 20107:00 amBUSTrading Statement
29th Jul 20105:47 pmBUSHolding(s) in Company
30th Jun 201011:58 amRNSResult of AGM
15th Jun 20105:17 pmRNSHolding(s) in Company
8th Jan 20102:34 pmRNSChange of Registered Office
13th Nov 20092:16 pmRNSDirectorate Change
13th Nov 20092:10 pmRNSPayment of dividend and proceeds of redemption
5th Nov 20092:01 pmRNSDe-listing from LSE
29th Oct 20092:00 pmRNSDividend Declaration
28th Oct 20092:19 pmRNSDirectorate Change
13th Aug 200912:00 pmRNSDirector/PDMR Shareholding
6th Aug 200911:39 amRNSDirector/PDMR Shareholding
27th Jul 20097:00 amRNSAnglo Platinum Interim Results
27th Jul 20097:00 amRNSAnglo Platinum Interim Results
24th Jul 20093:00 pmRNSDirectorate Change
17th Jul 200912:00 pmRNSChange to the Board of Directors
9th Jul 200910:58 amRNSBlocklisting Interim Review
9th Jul 200910:57 amRNSBlocklisting Interim Review
24th Jun 20094:00 pmRNSDirector/PDMR Shareholding
5th Jun 20092:58 pmRNSDealings by a director of major subsidiary
4th Jun 20093:08 pmRNSDirector/PDMR Shareholding
14th May 20093:01 pmRNSBEE transaction revised terms
30th Apr 20098:25 amRNSQuarterly Review and Production Report
29th Apr 200912:00 pmRNSDeclaration of preference dividend
30th Mar 20094:00 pmRNSResults of AGM
26th Mar 20099:24 amRNSNotice of AGM
13th Mar 200911:29 amRNSDirector/PDMR Shareholding
5th Mar 200911:10 amRNSDirectorate Change
12th Feb 20099:24 amRNSDirector/PDMR Shareholding
9th Feb 200910:38 amRNSFinal Results
9th Feb 20097:00 amRNSAnglo Platinum Results
9th Feb 20097:00 amRNSFinal Results
6th Jan 20092:14 pmRNSDirectorate Change
6th Jan 20097:00 amRNSBlocklisting Interim Review
6th Jan 20097:00 amRNSBlocklisting Interim Review
15th Dec 20083:30 pmRNSDirector/PDMR Shareholding
8th Dec 20083:30 pmRNSTiming of capex review
12th Nov 20089:30 amRNSAgreements with Anglo Platinum & Northam Platinum
5th Nov 20082:32 pmRNSSmelter Shutdown
4th Nov 20082:00 pmRNSDirector/PDMR Shareholding
27th Oct 20082:00 pmRNSDividend Declaration
23rd Oct 20082:57 pmRNSBEE restructuring agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.